利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.013 秒)

    MCH antagonists and their use in the treatment of obesity
    2.
    发明授权
    MCH antagonists and their use in the treatment of obesity 失效
    MCH拮抗剂及其在治疗肥胖中的应用

    公开(公告)号：US06472394B1

    公开(公告)日：2002-10-29

    申请号：US10023371

    申请日：2001-12-17

    申请人： Brian A. McKittrick ,  Jing Su ,  John W. Clader ,  Shengjian Li ,  Guihau Guo

    发明人： Brian A. McKittrick ,  Jing Su ,  John W. Clader ,  Shengjian Li ,  Guihau Guo

    IPC分类号： C07D40106

    CPC分类号： C07D401/06 ,  A61K31/445 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/4965 ,  A61K31/517 ,  C07D211/34 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

    摘要： Disclosed are compounds represented by structural formula I: or a pharmaceutically acceptable salt, ester or solvate thereof, wherein W is R1—CR3R12NR4C(O)— or R11C(O)NR4—; the dotted line is an optional double bond; X is —CHR8—, —C(O)—, or —C(═NOR9)—; Y is R1 is optionally substituted cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkyl-alkyl; R2 is optionally substituted aryl or heteroaryl; R3 is alkyl, aryl or heteroaryl; R4 and R12 are H or alkyl; R8 is H, alkyl or alkoxyalkyl; R9 is H, alkyl or arylalkyl; R10 is H, alkyl or aryl; R11 is or, when R2 is R6-heteroaryl or R10 is not H, R11 can also be R5-phenylalkyl; n is 1-3 and m is 1-5; and R14 is 1-3 substituents selected from H, alkyl, halogen, —OH, alkoxy and CF3; and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of eating disorders and diabetes.

    摘要翻译： 公开了由结构式I表示的化合物：或其药学上可接受的盐，酯或溶剂合物，其中W为R 1 -CR 3 R 12 NR 4 C（O） - 或R 11 C（O）NR 4 - ;虚线为任选的双键; X为-CHR 8 - ， - （O） - 或-C（= NOR9） - ; Y是R 1是任选取代的环烷基，环烷基烷基，芳基，芳基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基 - 烷基; R 2是任选取代的芳基或杂芳基; R 4是H，烷基或烷氧基烷基; R 9是H，烷基或芳基烷基; R 10是H，烷基或芳基; R 11是或者当R 2是R 6 - 杂芳基或R 10 不是H，R11也可以是R5-苯基烷基; n是1-3，m是1-5; R 14为1-3个选自H，烷基，卤素，-OH，烷氧基和CF 3的取代基;以及含有化合物的药物组合物和使用该化合物治疗进食障碍和糖尿病的方法。

    Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds
    5.
    发明申请
    Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds 有权
    取代的[4-（4-苯基 - 哌嗪-1-基） - 环己基] - 脲化合物

    公开(公告)号：US20070123542A1

    公开(公告)日：2007-05-31

    申请号：US11453128

    申请日：2006-06-14

    申请人： George Chiu ,  Peter Connolly ,  Jessica Liu ,  Steven Middleton ,  Virginia Pulito ,  Shengjian Li

    发明人： George Chiu ,  Peter Connolly ,  Jessica Liu ,  Steven Middleton ,  Virginia Pulito ,  Shengjian Li

    IPC分类号： A61K31/495 ,  C07D241/04

    CPC分类号： C07D295/155 ,  C07D295/135

    摘要： The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.

    摘要翻译： 本发明涉及式（I）的取代的[4-（4-苯基 - 哌嗪-1-基） - 环己基] - 脲化合物及其药学上可接受的形式，作为α1a / 用于治疗良性前列腺肥大和下尿路症状的肾上腺素受体调节剂。 本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法和作为药物的新用途以及治疗方法。